Alexion Deal Adds Up For AstraZeneca's Rare Disease Specialist CFO

Marc Dunoyer Previously Led GSK's Orphan Operations

The proposed $39bn acquisition of Alexion by AstraZeneca has a particular interest for its chief financial officer Marc Dunoyer who recently spoke to Scrip about his extensive experience in the rare disease space.

Marc Dunoyer
AstraZeneca CFO Marc Dunoyer

When AstraZeneca PLC was weighing up an offer to acquire Alexion Pharmaceuticals Inc., it certainly helped that its chief financial officer Marc Dunoyer was also an expert in rare diseases.

Dunoyer joined AstraZeneca from GlaxoSmithKline plc in June 2013, when CEO Pascal Soriot said that he "possessed the rare blend of financial, business and science experience," and while it is unusual for the head of finance at to have extensive clinical knowledge, the Frenchman told Scrip in a

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deals

More from Business

Most Favored Nation Policy ‘Lazy, Misguided,’ But US Price Reforms Politically ‘Inevitable’

 
• By 

Policy experts and pharma executives react to President Trump’s executive order on “equalizing” drug prices between the US and comparable nations at the ISPOR 2025 conference.

Merck KGaA Braces For Volatility But Does Not Expect Europe To Budge On Pricing

 

Shares are hit as German conglomerate lowers revenue forecast.

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By 

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.